Sumatriptan
Product Images NDC 54868-6052

4 FDA label images from Physicians Total Care, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 54868-6052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Sumatriptan Nasal Spray Sandoz 20 mg Label (20mg Package Label)

Sumatriptan Nasal Spray Sandoz 20 mg Label (20mg Package Label)
Label for SUMATRIPTAN 20MG NAS SPY distributed by Physicians Total Care, Inc., with NDC 54868-6052. It includes lot number, expiration date, and a barcode. Manufactured by Bridge Inc., Princeton NJ.*
FDA Label Image

Chemical Structure (E1539630 59d8 49ed 999e 3c0b4bf056a8 01)

Chemical Structure (E1539630 59d8 49ed 999e 3c0b4bf056a8 01)
Chemical structure diagram of sumatriptan showing its molecular framework with labeled functional groups and bonds.*
FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 120 Minutes* (E1539630 59d8 49ed 999e 3c0b4bf056a8 02)

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 120 Minutes* (E1539630 59d8 49ed 999e 3c0b4bf056a8 02)
A line graph showing estimated probability of response over time in minutes from initial dose for Sumatriptan. Four curves compare placebo and doses of 9 mg, 10 mg, and 30 mg, illustrating increasing probability percentages over a 120-minute period.*
FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Or Other Medication For Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment* (E1539630 59d8 49ed 999e 3c0b4bf056a8 03)

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Or Other Medication For Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment* (E1539630 59d8 49ed 999e 3c0b4bf056a8 03)
A line graph showing the estimated probability of remission or rescue over 24 hours after an initial dose, comparing placebo and three SUMATRIPTAN doses (5 mg, 10 mg, and 20 mg). The x-axis represents time in hours, and the y-axis represents the probability percentage, with all treatments increasing over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.